Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Indoco is comprehensively working on the remedial action plan
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
We now rank 3rd in pharmaceutical production by volume and 14th by value
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
Subscribe To Our Newsletter & Stay Updated
